The potential regulatory challenges associated with approving new antimicrobial agents targeting Bi(III)-bound NDM-1 may include demonstrating the safety and efficacy of the new agents, ensuring they meet regulatory standards for antimicrobial drugs, addressing potential resistance issues, and navigating the complex approval processes required for new drugs targeting specific microbial mechanisms.